KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Debt to Equity (2016 - 2025)

Pfizer (PFE) has disclosed Debt to Equity for 17 consecutive years, with $0.75 as the latest value for Q4 2025.

  • Quarterly Debt to Equity rose 3.34% to $0.75 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.75 through Dec 2025, up 3.34% year-over-year, with the annual reading at $0.75 for FY2025, 3.34% up from the prior year.
  • Debt to Equity for Q4 2025 was $0.75 at Pfizer, up from $0.66 in the prior quarter.
  • The five-year high for Debt to Equity was $1.12 in Q4 2021, with the low at $0.35 in Q2 2023.
  • Average Debt to Equity over 5 years is $0.63, with a median of $0.66 recorded in 2023.
  • The sharpest move saw Debt to Equity plummeted 64.66% in 2022, then skyrocketed 115.54% in 2023.
  • Over 5 years, Debt to Equity stood at $0.5 in 2021, then fell by 24.72% to $0.37 in 2022, then surged by 115.54% to $0.81 in 2023, then fell by 10.25% to $0.72 in 2024, then increased by 3.34% to $0.75 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.75, $0.66, and $0.69 for Q4 2025, Q3 2025, and Q2 2025 respectively.